MCID: PDT015
MIFTS: 22

Pediatric Supratentorial Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Pediatric Supratentorial Ependymoma

MalaCards integrated aliases for Pediatric Supratentorial Ependymoma:

Name: Pediatric Supratentorial Ependymoma 12
Pediatric Supratentorial Ependymoblastoma 12
Childhood Supratentorial Ependymoma 73
Pediatric Cerebral Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7502
UMLS 73 C0278650

Summaries for Pediatric Supratentorial Ependymoma

MalaCards based summary : Pediatric Supratentorial Ependymoma, also known as pediatric supratentorial ependymoblastoma, is related to ependymoma, and has symptoms including headache, nausea and seizures. The drugs Lenograstim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and spinal cord.

Related Diseases for Pediatric Supratentorial Ependymoma

Diseases related to Pediatric Supratentorial Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ependymoma 10.1

Symptoms & Phenotypes for Pediatric Supratentorial Ependymoma

UMLS symptoms related to Pediatric Supratentorial Ependymoma:


headache, nausea, seizures, vomiting

Drugs & Therapeutics for Pediatric Supratentorial Ependymoma

Drugs for Pediatric Supratentorial Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
4
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
5
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
6
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
7
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
8
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
11
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
15 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
18 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
20 Vitamin B Complex Phase 3,Phase 2,Not Applicable
21 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
29 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
30 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Emetics Phase 3
32 Peripheral Nervous System Agents Phase 3,Phase 1
33 Antiemetics Phase 3,Phase 1
34 BB 1101 Phase 3,Phase 2,Phase 1
35 Autonomic Agents Phase 3,Phase 1
36 Folate Nutraceutical Phase 3,Phase 2,Not Applicable
37 Vitamin B9 Nutraceutical Phase 3,Phase 2,Not Applicable
38
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
39
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
40
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
41
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
42
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
43
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
44
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
45
Tamoxifen Approved Phase 2 10540-29-1 2733526
46
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
47
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
48
Cyproheptadine Approved Phase 2 129-03-3 2913
49
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
50
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 liposomal vincristine sulfate;carboplatin;cyclophosphamide;etoposide;cisplatin
4 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
5 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
6 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
8 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
9 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
10 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
11 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
12 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
13 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
14 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
15 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
16 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
19 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
20 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Active, not recruiting NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
21 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
22 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
23 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
24 TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma Terminated NCT00074334 Phase 1, Phase 2
25 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
26 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
27 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
28 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
29 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
30 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
31 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
32 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
33 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
34 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
35 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
36 Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas Completed NCT00002753 Phase 1
37 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
38 DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
39 ABT-751 in Treating Young Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
40 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
41 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
42 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
43 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
44 Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Completed NCT00107458 Phase 1 valproic acid
45 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
46 Treatment of Children With Recurrent Refractory Brain/Solid Tumors and Recurrent Ependymoma Recruiting NCT03206021 Phase 1 5 Azacytidine
47 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
48 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
49 MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Terminated NCT00572182 Phase 1 MK-0752
50 Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate

Search NIH Clinical Center for Pediatric Supratentorial Ependymoma

Genetic Tests for Pediatric Supratentorial Ependymoma

Anatomical Context for Pediatric Supratentorial Ependymoma

MalaCards organs/tissues related to Pediatric Supratentorial Ependymoma:

41
Brain, Bone, Spinal Cord, Bone Marrow, T Cells, Liver

Publications for Pediatric Supratentorial Ependymoma

Articles related to Pediatric Supratentorial Ependymoma:

# Title Authors Year
1
Pediatric Supratentorial Ependymoma: Surgical, Clinical, and Molecular Analysis. ( 29917116 )
2018
2
Pediatric supratentorial ependymomas show more frequent deletions on chromosome 9 than infratentorial ependymomas: a microsatellite analysis. ( 19446744 )
2009

Variations for Pediatric Supratentorial Ependymoma

Expression for Pediatric Supratentorial Ependymoma

Search GEO for disease gene expression data for Pediatric Supratentorial Ependymoma.

Pathways for Pediatric Supratentorial Ependymoma

GO Terms for Pediatric Supratentorial Ependymoma

Sources for Pediatric Supratentorial Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....